Stockreport

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

Inhibikase Therapeutics, Inc.  (IKT) 
PDF -- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors -- -- Advancement of IkT-001Pro into a Late-Stage Clinical Trial P [Read more]